

Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: A case report. Werthmann Paul G, Kempenich Robert, Lang-Avérous G, Kienle Gunver S. *World Journal of Gastroenterology* 2019; 25(12): 1524-1530

[PMID:[30948915](#)DOI:[10.3748/wjg.v25.i12.1524](#)]

Long-Term Tumor-Free Survival in a Patient with Stage IV Epithelial Ovarian Cancer Undergoing High-Dose Chemotherapy and Viscum album Extract Treatment: A Case Report. Paul G Werthmann, MD1 ; Robert Kempenich, MD2 ; Gunver S Kienle, MD1,3. *Permanent Journal* 2019;23:18-025 E-pub: 12/13/2018

<https://doi.org/10.7812/TPP/18-025>

Long-term Survival of a Patient with Metastatic Esophageal Cancer under Adjunct Treatment with Viscum album Extracts – A Case Report. Paul G Werthmann, Robert Kempenich, Gunver S Kienle. Witten/Herdecke University. Universitäts Klinikum Freiburg. 2019. *Phytomedicine* 61:8-9

DOI:[10.1016/j.phymed.2019.09.094](#)

<https://www.arena-anthropomed.com/>

Abstract

Background

Since prostate cancer is the most frequently diagnosed malignancy among males, the treatment of this disease becomes more and more important. A number of well-established forms of treatment are available in conventional medicine. These treatments are effective, but patients often suffer from considerable side effects (particularly concerning their sexuality), leading to an increased interest in complementary treatments.

Objectives

Misteltoe therapy is a frequently applied complementary treatment in oncological practice, however, the state of knowledge regarding misteltoe therapy in prostate cancer is so far limited to very few publications.

Case reports

Three patients with prostate cancer refused conventional therapies, because they were worried to risk their quality of life (their sexuality in particular).

The first case, a fifty-two year old man with prostate cancer classified T1bNoMo with Gleason 6 (3+3). Diagnosed: 13/06/2006 after transurethral resection of the prostate for benign prostate enlargement, PSA level: 1,22 ng/ml before the operation. He refused radical prostatectomy and never followed conventional cancer therapy. Start with Iscucin® Populi therapy: 24/11/2006.

The second case, a fifty year old man with prostate cancer classified T1cNoMo with Gleason5(2+3), PSA level: 5,2 ng/ml. Diagnosed: 14/02/2006. He refused radical prostatectomy and never followed conventional cancer therapy. Start with Iscucin® Populi therapy: 12/03/2006.

The third case, a sixty-one year old man with prostate cancer classified T3aNoMo with Gleason 7 (3+4), PSA level: 13,6 ng/ml. Diagnosed: 22/02/2002. Initial treatment with radiotherapy and hormone therapy (Enantone®). This patient refused the continuation of the hormone therapy after 18 months of treatment. After a relapse (03/04/2006): Start with Iscucin® Populi therapy: 20/06/2006.

Patients were followed regularly with clinical examinations, PSA level and MRI investigations.

Results

The three patients showed an evidence of improvement of quality of life and no side effects were observed, in particular concerning their sexual life. Two cases showed a complete remission respectively after two and a half years and three years, and one case showed a partial remission after three years.

The role of Iscucin® Populi (WALA) therapy in prostate cancer should be evaluated in future clinical studies.c

Werthmann, P. G., Kempenich, R., & Kienle, G. S. (2019). Long-term survival of a patient with advanced esophageal cancer under adjunct treatment with *Viscum album* extracts—A case report. *Phytomedicine*, 61, 8-9.

Résumé

Dans ce **rapport de cas clinique**, les auteurs décrivent l'évolution d'un patient atteint d'un **cancer avancé de l'œsophage** qui a reçu, en complément des traitements conventionnels, des **extraits de *Viscum album*** (extraits de gui) en tant que thérapie adjuvante.

Les extraits de *Viscum album* sont souvent utilisés en médecine intégrative pour leurs effets potentiels sur **le système immunitaire** et la **qualité de vie** chez les patients cancéreux. Dans ce cas particulier, les auteurs rapportent une **survie à long terme** du patient malgré le pronostic généralement mauvais associé à ce type de cancer avancé.

Bien que l'article soit centré sur un seul patient et ne permette pas de conclusions générales, il **suggère l'intérêt possible d'étudier plus avant l'utilisation d'extraits de *Viscum album* comme traitement complémentaire**, notamment en raison de leur potentiel immunomodulateur

Background: Mistletoe (*Viscum album*) extracts (VAE) are frequently used as an adjunctive therapy in oncology for their purported immunomodulatory and quality-of-life benefits.

Case Presentation: This case report describes a patient with advanced esophageal cancer who received adjunct treatment with *Viscum album* extracts alongside standard oncological care.

Outcome: Despite the typically poor prognosis associated with advanced esophageal carcinoma, the patient experienced long-term survival under this combined treatment approach. The authors discuss the potential contribution of *Viscum album* extracts to this outcome and suggest that further research into its adjunctive use in cancer care is warranted.

Conclusion: The report highlights a single case of prolonged survival in advanced esophageal cancer with adjunctive VAE treatment, emphasizing the need for further clinical investigation.